The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Ore Huiying / Bloomberg / Getty Images Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...